TWD 70.2
(-2.9%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 592.5 Million TWD | 8.16% |
2022 | 547.8 Million TWD | 5.45% |
2021 | 519.51 Million TWD | 17.24% |
2020 | 443.13 Million TWD | 3.2% |
2019 | 429.38 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 169.6 Million TWD | 1.64% |
2024 Q1 | 166.87 Million TWD | 5.8% |
2023 Q4 | 157.73 Million TWD | 1.9% |
2023 FY | 592.5 Million TWD | 8.16% |
2023 Q3 | 154.79 Million TWD | 6.45% |
2023 Q2 | 145.41 Million TWD | 8.07% |
2023 Q1 | 134.55 Million TWD | -4.85% |
2022 FY | 547.8 Million TWD | 5.45% |
2022 Q4 | 141.4 Million TWD | 0.0% |
2021 FY | 519.51 Million TWD | 17.24% |
2020 FY | 443.13 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
BIONET Corp. | 1.12 Billion TWD | 47.441% |
DIVA Laboratories, Ltd. | 893.84 Million TWD | 33.713% |
Welgene Biotech Co.,Ltd. | 280.54 Million TWD | -111.195% |
Puriblood Medical Co., Ltd. | 125.26 Million TWD | -372.986% |
TFBS Bioscience Inc. | 231.91 Million TWD | -155.48% |